For all press and media enquiries please contact mediarelations@chiesi.com
Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an inhaled corticosteroid (ICS) / long-acting?2-agonist (LABA) / long-acting muscarinic antagonist (LAMA)…
Trimbow is the first extrafine formulation fixed triple combination therapy in a single inhaler to be approved for use in appropriate asthma patients. 1,2 This follows the 2017 approval of this therapeutic option for the treatment of appropriate moderate to severe chronic obstructive pulmonary…
Data from two randomised, double-blind, parallel-group, active-controlled studies on the efficacy and safety of single-inhaler triple therapy in adult patients with uncontrolled asthma is published in The Lancet for the first time TRIMARAN and TRIGGER compared the single-inhaler triple therapy…
Lamzede ® (velmanase alfa) is the first enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis (AM) AM is an ultra-rare disorder presenting a broad range of symptoms and its long-term prognosis is generally poor, with…
Lamzede ® (velmanase alfa) is the first pharmacological therapy for the treatment of Alpha- Mannosidosis (AM), an ultra-rare, disabling, genetic disorder 1 AM is a lysosomal storage disorder caused by the deficiency in the activity of the enzyme alpha-mannosidase, involved in the cellular breakdown…
Chiesi completed a long-term clinical study with its extrafine fixed-dose triple combination inhaler (Trimbow ® ) in a single pressurised metered dose inhaler (pMDI) for COPD patients. Trimbow met the primary endpoint showing superiority vs Ultibro ® in reducing COPD exacerbations. Full study…
Parma, Italy, July 24 2017 Chiesi Group (Chiesi), an international research-focussed healthcare company, today announced that the European Commission has granted the marketing authorisation for Trimbow® for the maintenance treatment in adult patients with moderate to severe chronic obstructive…
Chiesi is the first pharmaceutical company to have demonstrated with randomized clinical trials, two of which published in The Lancet 1,2, the efficacy of the triple extrafine combination to prevent exacerbations, improve symptoms and quality of life. Trimbow is the first fixed triple combination as…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
